Helix Biopharma Announces Fiscal 2005 Results

Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the year ended July 31, 2005. During the 2005 fiscal year, the Company strengthened its management team and Board of Directors while making progress with both clinical (Topical Interferon Alpha-2b) and pre-clinical (L-DOS47) programs. To further support both programs, the Company successfully raised additional capital from private placements.